Phase II
French company DBV Technologies is seeing some positive results from its milk allergy treatment.
ARCA biopharma announced positive headline results from its Phase IIb clinical trial of Gencaro, but investors aren’t buying the positive spin.
GW Pharmaceuticals announced that its pipeline compound GWP42006 failed to meet its primary endpoint in a Phase IIa proof of concept study for patients with focal seizures.
Johnson & Johnson is hoping its $100 million deal with Theravance will serve as a replacement for Remicade which lost patent protection.
Eli Lilly and its Korean collaborative partner Hanmi stopped a Phase II trial on an experimental rheumatoid arthritis treatment following less-than-stellar interim results.
A look at three drug approvals of vital importance to the company this year.
The study assessed two doses of RG7716 versus ranibizumab standard of care given as monthly intravitreal injections.
Another potential treatment for Alzheimer’s disease has been tossed into the rubbish bin.
The company eleased the pipeline update at its Q4 earnings report.
Since Emma Walmsley took over leadership at Glaxo, expectations have been both high and hypercritical.
PRESS RELEASES